Milin Acharya - Concepedia

Author

Milin Acharya

Janssen (United States)

Also Known As

Acharya, Milin, M Acharya, M. Acharya, Milin Acharya, Milin R Acharya, Milin R. Acharya, Monika Acharya

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Janssen (Belgium)National Cancer Institute Virginia Commonwealth University Center for Cancer Research

About

Milin Acharya is an author at Janssen (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	429
2	Biochemistry	2	2	52
3	Engineering	1	1	14
4	Health Sciences	1	1	118
5	Natural Sciences	1	1	38

Milin Acharya

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma Qin Ryan, Donna Headlee, Milin Acharya, Journal of Clinical Oncology	2005	406
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel Nicola F. Smith, Milin Acharya, Neil Desai, Cancer Biology & Therapy	2005	236
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma Philippe Moreau, Valérie Coiteux, Cyrille Hulin, Haematologica Hematological MalignancyProteasome InhibitionOncologyMetronomic TherapyHematology	2008	118
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma Donna Reece, Dan M. Sullivan, Sagar Lonial, Cancer Chemotherapy and Pharmacology Hematological MalignancyPharmacodynamic StudyOncologyRelapsed Multiple MyelomaHematology	2010	106
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer Kim N., Jennifer L. Spratlin, Christian Kollmannsberger, The Journal of Clinical Pharmacology	2015	101
A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects Milin Acharya, Martha Gonzalez, Geert Mannens, Xenobiotica	2012	61
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men Milin Acharya, Apexa Bernard, Martha Gonzalez, Cancer Chemotherapy and Pharmacology	2012	46
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor Milin Acharya, Alex Sparreboom, Edward A. Sausville, Cancer Chemotherapy and Pharmacology Histone ModificationsChromatinBiochemistryChromatin RemodelingMedicine	2005	38
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma David I. Quinn, John Nemunaitis, Jyotsna Fuloria, Clinical Pharmacokinetics Hematological MalignancyMolecular PharmacologyOncologyMedicineMetronomic Therapy	2009	37
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer Anthony W. Tolcher, K. N., Neal D. Shore, Cancer Chemotherapy and Pharmacology	2012	34

Page 1